Showing 8241-8250 of 9458 results for "".
- SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technologyhttps://practicaldermatology.com/news/skinbiotherapeutics-raises-capital-to-broaden-applications-for-skin-biome-technology/2459894/SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is being developed for use in cosmetics, infectio
- Rodan & Fields Takes on Teen Acne with Spotlesshttps://practicaldermatology.com/news/rodan-fields-takes-on-teen-acne-with-spotless/2459898/Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish R
- New Guidelines Offer SRT Treatment Recommendations for Skin Cancers, Keloidshttps://practicaldermatology.com/news/new-guidelines-offer-srt-treatment-recommendations-for-skin-cancers-keloids/2459897/Superficial Radiation Therapy (SRT) should be first-line therapy for appropriate non-melanoma skin cancers in appropriate patients, according to new consensus guidelines<
- Study Shows 97% Cure Rate for Superficial Radiation Therapy for BCC and SCChttps://practicaldermatology.com/news/study-shows-97-cure-rate-for-superficial-radiation-therapy-for-bcc-and-scc/2459900/A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100TM Superficial Radiation Therapy from Sensus Hea
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- Stelatopia Emollient Face Cream Now Available from Mustelahttps://practicaldermatology.com/news/stelatopia-emollient-face-cream-now-available-from-mustela/2459902/Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides a
- Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinomahttps://practicaldermatology.com/news/immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma/2459909/First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topa
- Key West Bans Sunscreens with Oxybenzone and Octinoxatehttps://practicaldermatology.com/news/key-west-bans-sunscreens-with-oxybenzone-and-octinoxate/2459911/Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate — two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. Fir
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Dr. Adam Friedman to Serve as Interim Chair of GW's Department of Dermatologyhttps://practicaldermatology.com/news/dr-adam-friedman-to-serve-as-interim-chair-of-gws-department-of-dermatology/2459915/The GW School of Medicine and Health Sciences (SMHS) and the GW Medical Faculty Associates (GW MFA) have selected Adam Friedman, MD, FAAD, professor of dermatology, to serve as the in